US2003152583A1PendingUtilityA1

Soluble herpesvirus glycoprotein complex vaccine

58
Assignee: UNIV PENNSYLVANIAPriority: Jul 25, 1994Filed: Feb 20, 2003Published: Aug 14, 2003
Est. expiryJul 25, 2014(expired)· nominal 20-yr term from priority
Inventors:Gary H. CohenRoselyn J. EisenbergTao PengGary Dubin
C12N 2710/16622A61K 38/00C07K 14/005A61K 48/00A61P 31/22A61K 39/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A vaccine comprising a soluble herpes simplex virus gHt-gL complex suspended in a pharmaceutically acceptable carrier.  
     
     
         2 . The vaccine of  claim 1 , wherein said herpes simplex virus is selected from the group consisting of herpes simplex virus type 1 and herpes simplex virus type 2.  
     
     
         3 . The vaccine of  claim 1 , wherein said herpes simplex virus is herpes simplex virus type 1.  
     
     
         4 . The vaccine of  claim 1 , wherein said gHt is from a herpes simplex virus selected from herpes simplex virus type 1 and herpes simplex virus type 2.  
     
     
         5 . The vaccine of  claim 1 , wherein said gL is from a herpes simplex virus selected from herpes simplex virus type 1 and herpes simplex virus type 2.  
     
     
         6 . The vaccine of  claim 1 , wherein said gHt is herpes simplex virus type 1 and comprising amino acid residues selected from the group consisting of 1-792, 1-648, 1-475, 1-324 and 1-275.  
     
     
         7 . The vaccine of  claim 1 , wherein said gHt is herpes simplex virus type 1 gHt comprising amino acids 1-324.  
     
     
         8 . The vaccine of  claim 1 , wherein said herpes simplex virus is herpes simplex virus type 1, said gHt comprises amino acids 1-792 and said gL comprises amino acids 1-168.  
     
     
         9 . The vaccine of  claim 1 , further comprising a substantially pure preparation of at least one of a herpes simplex virus gD, gB, or gC.  
     
     
         10 . A vaccine comprising an isolated DNA encoding a soluble herpes simplex virus gHt-gL complex suspended in a pharmaceutically acceptable carrier.  
     
     
         11 . The vaccine of  claim 10 , further comprising an isolated DNA encoding at least one of a herpes simplex virus gD, gB or gC.  
     
     
         12 . A herpes simplex virus neutralizing antibody which specifically binds to a soluble herpes simplex virus gHt-gL complex.  
     
     
         13 . An isolated DNA encoding a herpes simplex virus neutralizing antibody which specifically binds to a soluble herpes simplex virus gHt-gL complex.  
     
     
         14 . A method of immunizing a human patient against a herpes simplex virus infection comprising administering to said patient the vaccine of  claim 1 .  
     
     
         15 . A method of immunizing a human patient against a herpes simplex virus infection comprising administering to said patient the vaccine of  claim 9 .  
     
     
         16 . A method of immunizing a human patient against a herpes simplex virus infection comprising administering to said patient the vaccine of  claim 10 .  
     
     
         17 . A method of immunizing a human patient against a herpes simplex virus infection comprising administering to said patient the vaccine of  claim 11 .  
     
     
         18 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the vaccine of  claim 1 .  
     
     
         19 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the vaccine of  claim 9 .  
     
     
         20 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the vaccine of  claim 10 .  
     
     
         21 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the vaccine of  claim 11 .  
     
     
         22 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the herpes simplex virus neutralizing antibody of  claim 12  suspended in a pharmaceutically acceptable carrier.  
     
     
         23 . A method of treating a herpes simplex virus infection in a human patient comprising administering to said patient the isolated DNA of  claim 13  suspended in a pharmaceutically acceptable carrier.  
     
     
         24 . A preparation of a soluble herpes simplex virus gHt-gL complex.  
     
     
         25 . A substantially pure preparation of a soluble herpes simplex virus gHt-gL complex.  
     
     
         26 . The complex of  claim 24 , wherein said herpes simplex virus is selected from the group consisting of herpes simplex virus type 1 and herpes simplex virus type 2.  
     
     
         27 . The complex of  claim 26 , wherein said herpes simplex virus is herpes simplex virus type 1.  
     
     
         28 . The complex of  claim 24 , said complex being suspended in a pharmaceutically acceptable carrier.  
     
     
         29 . The complex of  claim 27 , wherein said gHt comprises amino acid residues selected from the group consisting of 1-792, 1-648, 1-475, 1-324 and 1-275.  
     
     
         30 . The complex of  claim 27 , wherein said gHt comprises amino acids 1-324.  
     
     
         31 . The complex of  claim 27 , wherein said gHt comprises amino acids 1-792 and said gL comprises amino acids 1-168.  
     
     
         32 . A cell, the DNA of said cell encoding a soluble herpes simplex virus gHt-gL complex.  
     
     
         33 . The cell of  claim 32 , wherein said cell is HL-7.  
     
     
         34 . A method of modifying a cell to render it capable of secreting a soluble herpes simplex virus gHt-gL complex comprising introducing into said cell DNA encoding a truncated form of herpes simplex virus gH being gHt and full length herpes simplex virus gL, wherein said gHt and said gL are expressed in and secreted from said cell.  
     
     
         35 . The method of  claim 34 , wherein said gHt comprises herpes simplex virus type 1 gH comprising amino acid residues selected from the group consisting of 1-792, 1-648, 1-475, 1-324 and 1-275.  
     
     
         36 . An isolated DNA comprising DNA encoding a herpes simplex virus gHt and a substantially full length herpes simplex virus gL.

Join the waitlist — get patent alerts

Track US2003152583A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.